Business Wire: Charles River Associates (CRA) Announces Conference Presentation on Strategies to Identify Rare Disease Patients at World Orphan Drug Congress Europe 2018
Charles River Associates (CRA) Announces Conference Presentation on Strategies to Identify Rare Disease Patients at World Orphan Drug Congress Europe 2018
Seeking Alpha: Sharp Therapeutics to Present Pipeline and Program Updates at World Orphan Drug Congress 2025
Sharp Therapeutics to Present Pipeline and Program Updates at World Orphan Drug Congress 2025
JD Supra: New FDA Drug Reforms: Congress Extends Voucher Incentive, Clarifies Orphan Exclusivity and Provides Greater Transparency for Q1/Q2 Generic Approvals
In legislation enacted on Feb. 3, 2026, Congress reauthorized the rare pediatric disease priority review voucher program, clarified the scope of orphan drug exclusivity (ODE) and mandated increased ...
New FDA Drug Reforms: Congress Extends Voucher Incentive, Clarifies Orphan Exclusivity and Provides Greater Transparency for Q1/Q2 Generic Approvals
JD Supra: Congress Reauthorizes the Rare Pediatric Disease Priority Review Voucher Program and Clarifies Orphan Drug Exclusivity
Congress Reauthorizes the Rare Pediatric Disease Priority Review Voucher Program and Clarifies Orphan Drug Exclusivity
The National Law Review: New FDA Drug Reforms: Congress Extends Voucher Incentive, Clarifies Orphan Exclusivity and Provides Greater Transparency for Q1/Q2 Generic Approvals
JD Supra: Oliver Twisted Again: After FDA’s Court Losses, Congress Approves FDA’s Standards on Orphan Drug Exclusivity
Last week, Congress enacted the Consolidated Appropriations Act of 2026. This legislation narrows the scope of the statutory protection for drugs for rare diseases and conditions under the Orphan Drug ...
Oliver Twisted Again: After FDA’s Court Losses, Congress Approves FDA’s Standards on Orphan Drug Exclusivity